Fibrous Meningioma
Disease Details
Family Health Simplified
- Description
- Fibrous meningioma is a type of benign brain tumor originating from the meninges, characterized by spindle-shaped cells and a collagen-rich matrix.
- Type
- Fibrous meningioma is a type of tumor classified under the WHO Grade I meningiomas, characterized by a pattern of spindle cells in a collagen-rich matrix. It is generally considered sporadic, with no specific type of genetic transmission commonly associated with it. However, some cases may involve genetic mutations, such as those in the NF2 gene, particularly in the context of neurofibromatosis type 2.
- Signs And Symptoms
-
Fibrous meningioma, also known as a fibroblastic meningioma, is a type of tumor that arises from the meninges, the protective layers covering the brain and spinal cord.
**Signs and Symptoms:**
1. **Headache**: Persistent and progressively worsening headaches are common.
2. **Seizures**: Some patients may experience seizures depending on the tumor's location.
3. **Neurological Deficits**: These can include weakness, numbness, or difficulty with coordination and balance.
4. **Cognitive or Personality Changes**: Depending on location, changes in behavior, memory, or other cognitive functions may occur.
5. **Visual Problems**: If the tumor affects areas near the optic nerves, vision issues may arise.
These symptoms can vary widely based on the tumor's size, location, and rate of growth. - Prognosis
- Fibrous meningioma, also known as a fibroblastic meningioma, generally has a favorable prognosis. It is typically a slow-growing, benign tumor that arises from the meninges, the protective layers covering the brain and spinal cord. Complete surgical removal usually results in a good outcome, with a low likelihood of recurrence. However, if the tumor is incompletely resected, there is a higher chance of recurrence, which may necessitate further treatment, such as additional surgery or radiation therapy. Regular follow-up with imaging is recommended to monitor for any signs of recurrence.
- Onset
- Fibrous meningioma, a subtype of meningioma, has no specific age of onset. It can occur in individuals of any age, although meningiomas in general are more commonly diagnosed in adults, particularly in middle-aged to older individuals.
- Prevalence
- The prevalence of fibrous meningioma is difficult to determine precisely because meningiomas are generally grouped together in epidemiological studies. However, meningiomas as a whole are the most common primary brain tumors in adults, accounting for about 35-40% of intracranial tumors. Fibrous meningiomas are a subtype, specifically within the World Health Organization (WHO) Grade I meningiomas, which are typically benign.
- Epidemiology
- Fibrous meningiomas, also known as fibroblastic meningiomas, are a subtype of meningiomas, which are typically benign tumors originating from the meninges—the protective membranes covering the brain and spinal cord. Epidemiologically, meningiomas are the most common primary central nervous system tumors, constituting about 30-35% of all primary intracranial neoplasms. They are more commonly diagnosed in middle-aged to elderly adults, with a higher incidence in females compared to males. Specifically, fibrous meningiomas account for approximately 4-7% of all meningiomas. Factors such as prior radiation exposure and certain genetic syndromes like neurofibromatosis type 2 can increase the risk of developing this type of tumor.
- Intractability
- Fibrous meningioma, a subtype of meningioma, is generally not considered intractable. These tumors are typically benign and slow-growing. Treatment often involves surgical resection, which can be curative, especially if the tumor is accessible and completely removed. In cases where surgery is not feasible, other treatments such as radiosurgery or radiation therapy may be effective. However, the prognosis can vary depending on the tumor's location, size, and the patient's overall health. Regular monitoring and follow-up care are essential to manage and address any potential recurrence or complications.
- Disease Severity
- Fibrous meningioma, also known as fibroblastic meningioma, is generally considered to be a benign tumor of the meninges, the protective membranes covering the brain and spinal cord. These tumors are typically slow-growing. Severity can vary based on factors like size, location, and potential impact on surrounding brain structures, but they are often treatable with surgical resection. The World Health Organization (WHO) classifies this type of meningioma as a Grade I tumor, indicating a generally favorable prognosis.
- Healthcare Professionals
- Disease Ontology ID - DOID:7211
- Pathophysiology
-
Fibrous meningioma, also known as fibroblastic meningioma, is a type of meningioma, which is a tumor that arises from the meninges, the membranous layers surrounding the brain and spinal cord.
**Pathophysiology:**
- **Cell Origin:** It originates from the arachnoid cap cells of the meninges.
- **Composition:** This variant is characterized by the presence of spindle-shaped cells and abundant collagenous matrix.
- **Growth Pattern:** The cells are arranged in interlacing bundles or fascicles.
- **Behavior:** Fibrous meningiomas typically grow slowly and are usually benign; however, they can exert pressure on adjacent brain tissue, leading to neurological symptoms.
- **Genetic and Molecular Factors:** Mutations in the NF2 gene on chromosome 22q are commonly associated with meningiomas, including the fibrous variant. Other genetic alterations can also play a role.
Nan: No Additional Note. - Carrier Status
- Fibrous meningioma, also known as fibroblastic meningioma, is a type of benign brain tumor that arises from the meninges, the membranes covering the brain and spinal cord. There is no carrier status for fibrous meningioma, as it is not an inherited condition. Its development is generally sporadic and not linked to genetic carriers in the way that genetic diseases like cystic fibrosis or sickle cell anemia are.
- Mechanism
-
Fibrous meningioma, also known as fibroblastic meningioma, is a type of meningioma characterized by a predominance of spindle-shaped cells and abundant collagen. These tumors are typically benign and arise from the meninges, the protective membranes covering the brain and spinal cord.
**Mechanism:**
Fibrous meningiomas develop from meningothelial (arachnoid cap) cells within the meninges. These tumors grow slowly and can cause symptoms by compressing adjacent brain tissue or spinal cord structures, depending on their location. The exact cause of meningiomas is not well understood, but factors such as genetic mutations, prior radiation exposure, and hormonal influences have been implicated.
**Molecular Mechanisms:**
1. **Genetic Mutations:**
- **NF2 Gene:** Loss or mutation of the Neurofibromin 2 (NF2) gene on chromosome 22 is commonly associated with meningioma formation. The NF2 gene encodes the protein merlin/schwannomin, which acts as a tumor suppressor.
- **SMO and AKT1 Genes:** Mutations in the Smoothened (SMO) and AKT1 genes, though less common, are also involved in some meningiomas.
2. **Signaling Pathways:**
- **PI3K/AKT/mTOR Pathway:** Activation of the PI3K/AKT/mTOR signaling pathway is observed in many meningiomas, contributing to cell growth, survival, and proliferation.
- **Hedgehog Pathway:** Mutations affecting the Hedgehog signaling pathway, such as in the SMO gene, can contribute to the tumorigenesis of meningiomas.
3. **Epigenetic Changes:**
- Alterations in DNA methylation and histone modification patterns have been observed in meningiomas, affecting gene expression and potentially contributing to tumor development and progression.
Understanding these molecular mechanisms provides potential targets for therapeutic interventions and improves the understanding of meningioma biology. - Treatment
-
Treatment options for fibrous meningioma typically include:
1. **Surgery**: The primary treatment for fibrous meningioma is surgical resection. The goal is to remove as much of the tumor as possible while preserving neurological function.
2. **Radiation Therapy**: If the tumor cannot be completely removed or if it recurs, radiation therapy may be used to target residual tumor cells. This can include conventional radiotherapy or stereotactic radiosurgery.
3. **Observation**: In some cases, particularly when the tumor is small and asymptomatic, a watch-and-wait approach with regular monitoring may be adopted.
4. **Medication**: Though not commonly used as a primary treatment, medications such as hormone therapy or chemotherapy might be considered in specific cases where surgery and radiation are not suitable.
It’s important to tailor the treatment approach based on the individual patient's case, tumor size, location, and overall health. - Compassionate Use Treatment
-
Fibrous meningioma is a type of brain tumor originating from the meninges, the membranes that surround the brain and spinal cord. Compassionate use, off-label, and experimental treatments for fibrous meningiomas might include:
1. **Compassionate Use Treatment:**
- Compassionate use may involve access to experimental therapies not yet widely available. These might include novel drugs, biological agents, or investigational devices specifically aimed at targeting meningiomas.
2. **Off-label Treatments:**
- **Bevacizumab (Avastin):** Although primarily approved for other cancers, Bevacizumab, an angiogenesis inhibitor, has been used off-label for recurrent or refractory meningiomas.
- **Hydroxyurea:** This chemotherapy agent has also been used off-label to manage meningiomas that are not amenable to surgery or radiotherapy.
3. **Experimental Treatments:**
- **Clinical Trials:** Patients may participate in clinical trials investigating new drugs, radiation techniques, or combination therapies specifically designed for meningiomas.
- **Immunotherapy:** Treatments like checkpoint inhibitors are being explored for their potential efficacy in meningiomas.
- **Gene Therapy and Targeted Treatments:** Investigations into specific genetic mutations associated with meningiomas are ongoing, with potential therapies targeting these alterations.
It's essential for patients to discuss these options with their healthcare providers to determine the best course of action based on the specific characteristics of their condition. - Lifestyle Recommendations
-
For fibrous meningioma, lifestyle recommendations include:
1. **Regular Medical Follow-up**: Routine check-ups with a neurologist or oncologist to monitor the condition and manage symptoms.
2. **Healthy Diet**: A balanced diet rich in fruits, vegetables, lean proteins, and whole grains to support overall health and immune function.
3. **Hydration**: Adequate water intake to maintain overall bodily functions.
4. **Physical Activity**: Regular, moderate exercise to improve overall wellness and potentially reduce fatigue.
5. **Stress Management**: Techniques such as meditation, yoga, or deep-breathing exercises to manage stress levels, which can impact overall health.
6. **Avoid Smoking and Limit Alcohol**: Both can have negative impacts on overall health and potentially worsening symptoms.
7. **Cognitive Activities**: Engaging in mentally stimulating activities like puzzles, reading, or learning new skills to support brain health.
8. **Sleep Hygiene**: Maintaining a regular sleep schedule and creating a restful sleeping environment to ensure adequate rest.
These recommendations should be tailored to individual needs and done under guidance from healthcare professionals. - Medication
-
Fibrous meningioma is a type of benign brain tumor arising from the meninges, the protective layers surrounding the brain and spinal cord. The primary treatment is usually surgical removal. Medications are typically used to manage symptoms or complications, rather than to treat the tumor itself. These may include:
1. Corticosteroids: To reduce inflammation and brain swelling.
2. Anticonvulsants: To prevent or control seizures.
3. Pain relievers: To manage headaches or other pain.
For cases where surgery is not feasible, additional treatments such as radiation therapy or radiosurgery may be considered. There are currently no specific medications available to shrink fibrous meningiomas directly. - Repurposable Drugs
- As of now, there is limited information on repurposable drugs specifically for fibrous meningioma. Treatment primarily involves surgical resection and possibly radiation therapy. Research into repurposing drugs from other cancers for meningioma is ongoing, but specific drugs have not been established for this type. Always consult medical professionals for the most up-to-date treatment options.
- Metabolites
- For fibrous meningioma, a specific list of metabolites directly associated with this type of tumor is not well-characterized in the literature. Typically, research on meningiomas, including fibrous meningiomas, looks at general metabolic alterations such as changes in glucose metabolism, amino acid metabolism, and lipid profiles. Advanced metabolic profiling or metabolomics studies might provide more detailed insights, but such data are often not specific to just fibrous meningiomas but rather meningiomas in general.
- Nutraceuticals
- For fibrous meningioma, nutraceuticals are not typically a primary mode of treatment. The focus is generally on surgical intervention and conventional therapies. However, some studies have suggested that certain nutraceuticals like omega-3 fatty acids, curcumin, and resveratrol may have potential benefits in supporting overall brain health and potentially inhibiting tumor growth due to their anti-inflammatory and antioxidant properties. Always consult with a healthcare professional before starting any new supplement regimen.
- Peptides
- Fibrous meningioma, also known as fibroblastic meningioma, is a type of brain tumor originating from the meninges. Peptides relevant to this condition could include those that influence tumor growth and cellular signaling, such as somatostatin analogs used in diagnostic imaging or potential therapeutic interventions. Nanoparticles (nan) are being explored for targeted drug delivery systems to treat meningiomas more effectively, aiming to improve the delivery of chemotherapeutic agents directly to the tumor site while minimizing systemic side effects.